Marinus Pharmaceuticals to Be Added to the Russell 2000 and Russell 3000 Index
June 21 2018 - 7:30AM
Marinus’ addition to the indexes will be
effective June 22, 2018, after market close
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”,
“Marinus”), a biopharmaceutical company dedicated to the
development of innovative therapeutics to treat epilepsy and
neuropsychiatric disorders, announced that it will be added to
the Russell 2000® and Russell 3000® Indexes,
effective Friday, June 22, 2018, after market close.
“We are pleased with Marinus’ addition to
the Russell indexes,” said Christopher M. Cashman,
Chief Executive Officer of Marinus. “We are committed to advancing
the development of ganaxolone to improve the lives of children and
mothers suffering from neuropsychiatric disorders and building
shareholder value.”
About FTSE Russell Russell US Indexes are the
leading US equity benchmarks for institutional investors. This
broad range of US indexes allow investors to track current and
historical market performance by specific size, investment style
and other market characteristics. All Russell US Indexes are
subsets of the Russell 3000® Index, which includes the
well-known large cap Russell 1000® Index and small
cap Russell 2000® Index. The Russell US Indexes are
designed as the building blocks of a broad range of financial
products, such as index tracking funds, derivatives and Exchange
Traded Funds (ETFs), as well as being performance benchmarks.For
more information on the FTSE Russell, go to the FTSE Russell
website.
About Marinus
Pharmaceuticals
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company
dedicated to the development of ganaxolone, which offers a new
mechanism of action, demonstrated efficacy and safety, and
convenient dosing to improve the lives of patients suffering from
epilepsy and neuropsychiatric disorders. Ganaxolone is a positive
allosteric modulator of GABAA that acts on a well-characterized
target in the brain known to have anti-seizure, anti-depressant and
anti-anxiety effects. Ganaxolone is being developed in three
different dose forms (IV, capsule and liquid) intended to maximize
therapeutic reach to adult and pediatric patient populations in
both acute and chronic care settings. Marinus has initiated
the first ever pivotal study in children with CDKL5 deficiency
disorder, a rare form of epilepsy, and is currently conducting
studies in patients with postpartum depression and refractory
status epilepticus. For more information visit
www.marinuspharma.com. Please follow us on Twitter:
@MarinusPharma.
Forward-Looking Statements
To the extent that statements contained in this press release
are not descriptions of historical facts regarding Marinus, they
are forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995. Words such as “may”, “will”, “expect”, “anticipate”,
“estimate”, “intend”, “believe”, and similar expressions (as well
as other words or expressions referencing future events, conditions
or circumstances) are intended to identify forward-looking
statements. Examples of forward-looking statements contained
in this press release include, among others, statements regarding
our interpretation of preclinical studies, development plans for
our product candidate, including the development of dose forms, the
clinical trial testing schedule and milestones, the ability to
complete enrollment in our clinical trials, interpretation of
scientific basis for ganaxolone use, timing for availability and
release of data, the safety, potential efficacy and therapeutic
potential of our product candidate and our expectation regarding
the sufficiency of our working capital. Forward-looking statements
in this release involve substantial risks and uncertainties that
could cause our clinical development programs, future results,
performance or achievements to differ significantly from those
expressed or implied by the forward-looking statements. Such
risks and uncertainties include, among others, the uncertainties
inherent in the conduct of future clinical trials, the timing of
the clinical trials, enrollment in clinical trials, availability of
data from ongoing clinical trials, expectations for regulatory
approvals, the attainment of clinical trial results that will be
supportive of regulatory approvals, and other matters, including
the development of formulations of ganaxolone, and the availability
or potential availability of alternative products or treatments for
conditions targeted by the Company that could affect the
availability or commercial potential of our drug candidates.
Marinus undertakes no obligation to update or revise any
forward-looking statements. For a further description of the
risks and uncertainties that could cause actual results to differ
from those expressed in these forward-looking statements, as well
as risks relating to the business of the Company in general, see
filings Marinus has made with the Securities and Exchange
Commission.
CONTACT: Lisa M. CaperelliExecutive Director,
Investor & Strategic RelationsMarinus Pharmaceuticals,
Inc.484-801-4674lcaperelli@marinuspharma.com
Marinus Pharmaceuticals (NASDAQ:MRNS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Marinus Pharmaceuticals (NASDAQ:MRNS)
Historical Stock Chart
From Sep 2023 to Sep 2024